Discover the new migraine medications, such as monoclonal antibodies and gepants, that are changing migraine treatment for ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

Pfizer has agreed to pay $59.75 million to settle claims that Biohaven Pharmaceutical Holding Co., which it acquired in 2022, defrauded Medicare and other healthcare programs by paying kickbacks ...

Pfizer has agreed to pay $59.7m to resolve illegal payments to healthcare professionals made by Biohaven Pharmaceuticals, a biopharma it acquired over two years ago. The charges allege that ...

The scheme took place from March 1, 2020, through Sept. 30, 2022. Pfizer bought Biohaven in October 2022. PFIZER'S PAXLOVID FAILS AS 15-DAY TREATMENT FOR LONG COVID, STUDY FINDS Prosecutors said ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Pfizer Inc's PFE subsidiary Biohaven Ltd BHVN released an updated investor presentation with additional data on the company's BHV-1300 program, a potential competitor to FcRn-targeting ...

Biohaven Ltd Business and Pipeline Overview - Plenty Of Experience, Plenty Of Assets To Work With It certainly seems as though Pfizer's buyout of Biohaven, the original, was all about the migraine ...

Biohaven hit the jackpot with its Pfizer deal On 05/10/2022 the companies announced a deal in which Pfizer (PFE) acquired Biohaven assets in a deal valued at $11.6 billion. Biohaven's stock soared ...

A new, slimmed-down Biohaven issued its debut earnings release post-Pfizer split, touting a $301.9 million fundraising, new executive staffers and a pipeline stocked with therapies to test in ...

Pharmaceutical giant Pfizer Inc. on Monday completed its $11.6 billion acquisition of New Haven’s Biohaven Pharmaceutical Holding Company Ltd., maker of migraine drug Nurtec ODT. The deal gives ...